Development of a patient/proxy-reported instrument for pediatric antibiotic-associated diarrhea

Samaneh Khanpour Ardestani1, Joan L Robinson1, Hsing Jou1

  • 1Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Plos One
|June 4, 2025
PubMed

Insights

This study developed a new tool to measure pediatric antibiotic-associated diarrhea (PAAD). The developed instrument shows promise for assessing PAAD incidence and severity in children.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Trial Methodology
  • Patient-Reported Outcomes

Background:

  • Antibiotic-associated diarrhea (AAD) is a common adverse effect in children.
  • Existing measures do not adequately capture the incidence and severity of pediatric AAD.
  • A validated patient/proxy-reported measure is needed for both inpatient and outpatient settings.

Purpose of the Study:

  • To develop and validate a patient/proxy-reported instrument for pediatric antibiotic-associated diarrhea (PAAD).
  • To assess the incidence and severity of PAAD in pediatric populations.
  • To establish content and construct validity of the new PAAD measure.

Main Methods:

  • Engaged a patient advisory group in the development process.
  • Developed instrument items from existing validated instruments, a core outcome measurement set, and stakeholder input.
  • Conducted a prospective observational study of children (birth to 17 years) prescribed antibiotics, assessing them daily for two weeks post-therapy.

Main Results:

  • Analyzed data from 48 eligible participants after 38% loss to follow-up.
  • Reported a wide range of PAAD incidence risks (27%-83%) based on different definitions.
  • Observed higher PAAD incidence in younger children (≤ 3 years) and found significant correlation between the PAAD severity score and parent-reported severity.

Conclusions:

  • The developed PAAD instrument is the first of its kind for measuring incidence and severity.
  • The instrument demonstrates content and construct validity.
  • Larger studies are recommended to further analyze the reliability of the severity scale.
Abstract